Cited by 746Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and TreatmentsBlood Pressure and Hypertension Studies

Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association

Open access
Iadecola, Costantino, Yaffe, Kristine, Biller, José, Bratzke, Lisa C., Faraci, Frank M., Gorelick, Philip B., Gulati, Martha, Kamel, Hooman +5 more·2016·Hypertension

Abstract

Background—: Age-related dementia, most commonly caused by Alzheimer disease or cerebrovascular factors (vascular dementia), is a major public health threat. Chronic arterial hypertension is a well-established risk factor for both types of dementia, but the link between hypertension and its treatment and cognition remains poorly understood. In this scientific statement, a multidisciplinary team of experts examines the impact of hypertension on cognition to assess the state of the knowledge, to identify gaps, and to provide future directions. Methods—: Authors with relevant expertise were selected to contribute to this statement in accordance with the American Heart Association conflict-of-interest management policy. Panel members were assigned topics relevant to their areas of expertise, reviewed the literature, and summarized the available data. Results—: Hypertension disrupts the structure and function of cerebral blood vessels, leads to ischemic damage of white matter regions critical for cognitive function, and may promote Alzheimer pathology. There is strong evidence of a deleterious influence of midlife hypertension on late-life cognitive function, but the cognitive impact of late-life hypertension is less clear. Observational studies demonstrated a cumulative effect of hypertension on cerebrovascular damage, but evidence from clinical trials that antihypertensive treatment improves cognition is not conclusive. Conclusions—: After carefully reviewing the literature, the group concluded that there were insufficient data to make evidence-based recommendations. However, judicious treatment of hypertension, taking into account goals of care and individual characteristics (eg, age and comorbidities), seems justified to safeguard vascular health and, as a consequence, brain health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hyp.0000000000000053

Cites

334 of 334 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Vascular risk factors including hypertension, diabetes, hyperlipidemia, and cardiovascular disease, as well as environment and lifestyle, all affect cerebrovascular and BBB dysfunction.

    “Vascular risk factors including hypertension (169, 272), diabetes (43, 110), hyperlipidemia (74), and cardiovascular disease (594), as well as environment (e.g., pollution) (87-89, 207) and lifestyle (e.g., obesity, sedentary lifestyle) (281, 643) all affect cerebrovascular and BBB dysfunction (429, 571), and may influence onset and progression of AD.”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [272]

    The Blood-Brain Barrier and Vascular Function sections (page not provided) report that hypertension disrupts BBB integrity and cerebrovascular function. The source discusses other risk factors in relation to cognition, but these passages do not establish that diabetes, hyperlipidemia, cardiovascular disease, pollution, obesity, and sedentary lifestyle all cause cerebrovascular and BBB dysfunction. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Evidence suggests that midlife may be a critical period when exposure to high blood pressure is likely to increase risk of poorer cognition in late life.

    “The evidence suggests that midlife may represent a critical period when exposure to high blood pressure is likely to increase risk of poorer cognition in late-life (8).”
  • Few trials of antihypertensive agents have included cognitive outcomes.

    “Few trials of antihypertensive agents have included cognitive outcomes and each trial has, almost inevitably, focused on a differing population group and used differing treatment regimens, inclusion criteria, blood pressure targets and in general relatively short follow up (8).”
  • There is emerging evidence for taking a life-course approach to exposure because it may account for varying exposure levels over time.

    “There is now also emerging evidence for taking a life-course approach to exposure not least as the latter may take account of varying exposure levels over time (8, 9, 10).”
  • Antihypertensive trials have differed in population group, treatment regimens, inclusion criteria, blood pressure targets, and follow-up length.

    “Few trials of antihypertensive agents have included cognitive outcomes and each trial has, almost inevitably, focused on a differing population group and used differing treatment regimens, inclusion criteria, blood pressure targets and in general relatively short follow up (8).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [89]Lezak M Neuropsychological Assessment New York, NY Oxford University Press 2004

Cited by

Sorted by citations

Authors
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., Saczynski, J. S., Seshadri, S., & Zeki Al Hazzouri, A.
Venue
Hypertension
Published
2016-12
Volume
68
Issue
6
Pages
e67-e94
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2530115453
Cited by
746
References
334
Citations by year
2026: 61 · 2025: 68 · 2024: 78 · 2023: 79 · 2022: 77 · 2021: 85 · 2020: 93 · 2019: 95 · 2018: 64 · 2017: 42 · 2016: 1
FWCI
59.81
Type
journal article
Language
en
Open access
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute on Aging (P30AG010129, K01AG047273)
  • National Institute of Neurological Disorders and Stroke (R37NS089323, R01NS017950)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
cognitive function, dementia, Alzheimer's disease, vascular dementia, white matter ischemia, cerebral vasculature, antihypertensive therapy, midlife hypertension, cerebrovascular injury, brain health
MeSH terms
Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, American Heart Association, Antihypertensive Agents, Cognition Disorders, Female, Follow-Up Studies, Humans, Hypertension, Male, Severity of Illness Index, Sex Factors, United States, Dementia, Vascular, Practice Guidelines as Topic, Disease Progression, Risk Assessment, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review